Trade Practices & Advertising (FTC)

Reference 15 - Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients

Reference 16 - Evaluating the Role of Solubility in Oral Absorption of

Reference 17 - In Silico Modelling Approach for the Evaluation of

Reference 18 - Bioequivalence Studies for Generic Drug Development

Reference 19 - Improving the Dissolution Rate of the Anticancer Drug Dabrafenib

Reference 20 - Citizen Petitions and Petitions for Stay of Action Subject to Section 505q of the Federal Food Drug and Cosmetic Act

Reference 21 - Draft Guidance on Rifaximin

Reference 22 - Bioequivalence safety and tolerability of imatinib tablets compared with capsules

Agency Information Collection Activities; Proposed Collection; Comment Request; Extension

Agency Information Collection Activities; Proposed OMB Generic Clearance; Comment Request; Generic Clearance for Information Collection Using Voluntary Surveys for Studies Conducted by the Federal Trade Commission Bureau of Economics To Support the FTC’s Missions To Protect Consumers and Competition